SureTrader
Home > Boards > US Listed > Biotechs > NanoViricides Inc. (NNVC)

As if they never mentioned many of their

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Its_lose_not_loose Member Profile
Member Level 
Followed By 7
Posts 4,690
Boards Moderated 0
Alias Born 09/11/13
160x600 placeholder
NanoViricides Files Quarterly Report for Period Ending December 31, 2017 PR Newswire (US) - 2/21/2018 7:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 2/20/2018 1:55:19 PM
Notification That Quarterly Report Will Be Submitted Late (nt 10-q) Edgar (US Regulatory) - 2/14/2018 5:57:04 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/15/2017 10:29:10 AM
Nanoviricides Initiates a Safety/Toxicology Study of Its Leading Shingles Candidates PR Newswire (US) - 12/6/2017 7:00:00 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 11/22/2017 4:23:23 PM
NanoViricides Files Quarterly Report for Period Ending September 30, 2017 PR Newswire (US) - 11/20/2017 7:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/14/2017 5:25:18 PM
Revised Proxy Soliciting Materials (definitive) (defr14a) Edgar (US Regulatory) - 11/8/2017 5:18:02 PM
NanoViricides Provides Further Details on Its Herpes-Induced Acute Retinal Necrosis Animal Study to be Presented On November ... PR Newswire (US) - 11/6/2017 7:00:00 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 10/27/2017 6:08:02 AM
Excellent Results in Inhibiting Shingles Virus in Human Skin: NanoViricides Extends Agreement with SUNY Upstate Medical Cente... PR Newswire (US) - 10/26/2017 7:00:00 AM
NanoViricides to Present Results On Successful Treatment Of Herpes-Induced Acute Retinal Necrosis at the Annual Meeting of th... PR Newswire (US) - 10/17/2017 7:00:00 AM
NanoViricides Has Filed Annual Report, Says Company Has Sufficient Cash To Advance Into Clinical Trials PR Newswire (US) - 9/29/2017 7:30:00 AM
Annual Report (10-k) Edgar (US Regulatory) - 9/28/2017 4:51:22 PM
NanoViricides, Inc. Announces its CEO Dr. Seymour to Present at the 19th Annual Rodman & Renshaw Global Investment Conference... PR Newswire (US) - 9/11/2017 9:04:00 AM
NanoViricides Reports Its Drug Candidates Significantly Reduced the Extent of Shingles Virus Infection of Human Skin PR Newswire (US) - 7/10/2017 7:00:00 AM
NanoViricides' Poster "Novel NanoviricidesĀ® Highly Effective Against Varicella Zoster Virus in Cell Culture" to be Presented... PR Newswire (US) - 6/26/2017 9:00:00 AM
NanoViricides Abstract Accepted for Poster Presentation at the 2017 Annual Meeting of American Society of Virology PR Newswire (US) - 6/20/2017 7:00:00 AM
NanoViricides CEO to Present Information on Its Topical Shingles Treatment At the 2017 Marcum Investor Conference in New York... PR Newswire (US) - 6/13/2017 7:00:00 AM
NanoViricides Reports Excellent Inhibitory Effects of Its Topical Shingles Treatment Candidates Against VZV in Multiple Cell ... PR Newswire (US) - 6/6/2017 5:30:00 PM
NanoViricides Files Quarterly Report for Period Ending 2017-03-31 PR Newswire (US) - 5/16/2017 7:50:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/15/2017 5:03:04 PM
NanoViricides CEO Dr. Seymour to Present an Update on the Company at The Planet Microcap Showcase - 2017 in Las Vegas; Compan... PR Newswire (US) - 4/26/2017 5:00:00 PM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 4/26/2017 6:02:18 AM
Its_lose_not_loose Member Level  Friday, 11/10/17 07:02:16 PM
Re: leifsmith post# 135939
Post # of 137939 
As if they never mentioned many of their countless other failures or misrepresentations.

It would be dangerous to invest in NNVC at this juncture.


"Who would claim to be one who was not?"
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist